Cancer Metabolism And Immune Evasion
What is this
This trend focuses on the research of metabolic barriers that inhibit T cell activation in the context of cancer, particularly clear cell renal cell carcinoma and other malignancies. It encapsulates a series of studies that span cellular metabolism and immunosuppressive mechanisms in the tumor microenvironment.
Why it matters
Cancer immunotherapy is a rapidly evolving field, and addressing metabolic constraints can unlock more effective treatments for resistant cancers. As the global focus shifts to precision medicine, breakthroughs in this area could significantly alter therapeutic pathways.
Investment angle
Investors might consider exposure to biotech firms and pharmaceuticals that are advancing immuno-oncology solutions, especially those researching metabolic modulation. Investment vehicles such as specialized biotech ETFs or targeted venture capital investments in early-stage companies could be promising.
A solid but high-risk investment play in breakthrough cancer research, offering reasonable potential in a booming market. Investability: 7/10
History
| date | signals | new | substance |
|---|---|---|---|
| 2026-03-06 | 32 | 100% | |
| 2026-03-18 | 231 | +199 | 100% |
| 2026-03-30 | 237 | +6 | 100% |
| 2026-04-12 | 238 | +1 | 100% |
| 2026-04-24 | 248 | +10 | 100% |
| 2026-05-06 | 257 | +9 | 100% |
| 2026-05-20 | 266 | +9 | 100% |
| 2026-06-02 | 270 | +4 | 100% |
| 2026-06-14 | 278 | +8 | 100% |
| 2026-06-26 | 280 | +2 | 100% |
| 2026-07-08 | 288 | +8 | 100% |
| 2026-07-20 | 292 | +4 | 100% |
| 2026-08-01 | 296 | +4 | 100% |
| 2026-08-13 | 300 | +4 | 100% |
Evidence
- 2026-08-09NIH RePORTERDefining the role of Acss2 in T cell adaptation to metabolic stress · detail
- 2026-08-09NIH RePORTERRewired Metabolism and Immunosuppression in MYCN-driven Neuroblastoma · detail
- 2026-08-09PubMedTransforming Cancer Treatment: Integrative Strategies Targeting the Tumor Microenvironment through Biological Innovation and Artificial Intelligence. · detail
- 2026-08-03PubMedCancer drug response and resistance: molecular mechanisms and combating strategies. · detail
- 2026-07-29PubMedLipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer. · detail
- 2026-07-28PubMedHDAC6 orchestrates NK cell maturation and antitumor immunity. · detail
- 2026-07-25PubMedDecoding the tumor-aging axis: from bench to clinical. · detail
- 2026-07-25PubMedTargeting PCNA in Cancer: A Paradigm Shift from Static Inhibition to Dynamic Network Modulation. · detail
- 2026-07-20PubMedProtein arginine methyltransferase (PRMT8) in cancer: Genomic alterations, subcellular dynamics, and clinical implications. · detail
- 2026-07-20PubMedExosomes in cancer drug resistance: dual roles in therapy failure and emerging precision therapeutics. · detail
- 2026-07-12PubMedAnoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies. · detail
- 2026-07-10OpenAlexEpigenetic silencing of TBX20 and its association with tumor immune infiltration in colorectal cancer · detail
- 2026-07-06NIH RePORTERImpact of RB activation on the pancreatic cancer epigenome and tumor microenvironment · detail
- 2026-07-06NIH RePORTERTargeting TOX-Imposed Epigenetic and Transcriptional Circuits to Restore T Cell Function in Cancer · detail
- 2026-07-04PubMedMetabolic enzyme-based cancer therapy: Mechanisms, delivery strategies, and translational challenges. · detail
- 2026-07-03PubMedConstruction and validation of a folate metabolism-related gene signature for prognosis prediction, immune landscape characterization, and molecular subtyping in glioma. · detail
- 2026-07-02PubMedKIAA0101 in human cancers: From biomarker discovery to therapeutic targeting. · detail
- 2026-06-30PubMedThe m6A Epitranscriptome in Cancer Therapy Resistance: From Cellular Plasticity and Metabolic Rewiring to Immune Escape and Therapeutic Targeting. · detail
- 2026-06-29PubMedActivation of the cGAS-STING pathway contributes to cancer-related fatigue in a murine model of head and neck cancer. · detail
- 2026-06-27PubMedEphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer. · detail